Exelixis (EXEL) Misses Q1 EPS by 6c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exelixis (EXEL) PT Lowered to $27 at RBC Capital
May 1, 2024 6:30 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Exelixis (NASDAQ: EXEL) to $27.00 (from $28.00) while maintaining a Outperform rating.
The analyst comments "Cabometyx sales were notably lighter than typical though 1Q softness is a trend (also in '22 & '23) and we... More
